Orforglipron is a once-daily oral GLP-1 receptor agonist tablet. In the United States it is approved as Foundayo for chronic weight management in adults, together with a reduced-calorie diet and more physical activity.[1][2]
This page explains the medicine using official sources and lists 4 brands: the originator Foundayo plus 3 other products as listed by their suppliers. It is not a complete global list, and regulatory status differs by product and country.[4]
Availability enquiries are handled by Medicine for World. Submission of an enquiry does not confirm regulatory eligibility, supply or delivery. Ownership and commercial disclosure
Orforglipron is the international non-proprietary name of a small-molecule (non-peptide) agonist of the glucagon-like peptide-1 (GLP-1) receptor. Unlike injectable GLP-1 medicines, it is a tablet, and unlike oral semaglutide it can be taken at any time of day with or without food or water restrictions.[1][2]
According to the current US prescribing information (DailyMed, revised July 2026), Foundayo is indicated, together with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in:[1]
In the United Kingdom, the MHRA authorised orforglipron on 10 August 2026 for weight management in adults and for adults with insufficiently controlled type 2 diabetes. Approved uses differ between countries.[3]
Whether orforglipron is suitable, and at which dose, is decided by the treating physician. Full warnings are in the official product information:
The products below are included for identification and availability-enquiry purposes. Inclusion does not mean that a product is authorised, approved, therapeutically equivalent or available in every country. Confirm regulatory status with the relevant national medicines authority.
Products are listed in alphabetical order. The list is not a ranking and makes no claim that one product is better than another.[4]
No product matches these filters.
Product listing data last checked October 5, 2026.
Foundayo is the originator orforglipron medicine. It was discovered by Chugai Pharmaceutical, developed by Eli Lilly and Company, and approved by the US Food and Drug Administration on 1 April 2026 as the first GLP-1 pill for weight loss that can be taken at any time of day without food or water restrictions. Other products represented as containing orforglipron are made by other manufacturers and sold under their own brand names.[1][2]
The originator is shown here separately from the other listed products.
This comparison covers identity and listing information only. It does not establish regulatory approval, pharmaceutical equivalence, bioequivalence, quality, safety or clinical effectiveness.
| Attribute | Other listed orforglipron products | Originator (Foundayo) |
|---|---|---|
| Active substance | Orforglipron, as listed. Salt form and formulation are not stated in the product listings.[4] | Orforglipron[1] |
| Brand name | Each manufacturer's own brand name (3 products listed)[4] | Foundayo[1] |
| Company | 3 different manufacturers, as listed[4] | Eli Lilly and Company[1] |
| Dosage form | Tablet, as listed[4] | Film-coated tablet[1] |
| Strengths | Listed in steps between 0.8 mg and 17.2 mg; one product also lists 8.6 mg, which is not a US label strength[4] | 0.8 / 2.5 / 5.5 / 9 / 14.5 / 17.2 mg[1] |
| Regulatory approval | Varies by product and country. Not independently verified for this page; check with your national medicines authority. | US FDA 1 April 2026 · UK MHRA 10 August 2026[2][3] |
| Classification | Product represented by its manufacturer or supplier as containing orforglipron. Regulatory classification must be confirmed in the relevant jurisdiction.[4] | Originator product[1] |
The information below summarises the US prescribing information. It is not complete; read the full label and talk to your doctor.[1]
| Side effect | Reported in |
|---|---|
| Nausea | 35% |
| Diarrhoea | 25% |
| Constipation | 24% |
| Vomiting | 24% |
| Abdominal pain | 14% |
| Indigestion (dyspepsia) | 13% |
| Headache | 9% |
| Fatigue | 9% |
| Bloating (abdominal distension) | 8% |
| Belching | 8% |
| Reflux (GERD) | 7% |
| Flatulence | 6% |
| Hair loss | 5% |
Orforglipron is taken by mouth once a day, at any time of day, with or without food. Tablets are swallowed whole and must not be broken, crushed or chewed. The dose is increased gradually to reduce stomach and bowel side effects. Your doctor decides the dose.[1]
| Step | Daily dose | When |
|---|---|---|
| 1 | 0.8 mg | Starting dose |
| 2 | 2.5 mg | After at least 30 days |
| 3 | 5.5 mg | After at least 30 more days |
| 4 | 9 mg, 14.5 mg or 17.2 mg | Further increases, each after at least 30 days, according to response and tolerability |
Maximum dose: 17.2 mg once daily. The strengths in the table are label information, not a personal recommendation.[1]
In a 72-week study of 3,127 adults with obesity or overweight without diabetes, average body-weight change was −7.4% (5.5 mg), −8.3% (9 mg) and −11.1% (17.2 mg), compared with −2.1% with placebo. 71.5% of people on 17.2 mg lost at least 5% of their weight (placebo 26.8%).[1]
In a 72-week study of 1,613 adults with overweight and type 2 diabetes, average weight change was −5.1%, −7.0% and −9.6% for the same doses, compared with −2.5% with placebo.[1]
Tell us your country and the product information you are looking for.
Medicine for World reviews destination-country restrictions and may request prescription or treatment documentation through a secure channel.
If the request can lawfully be supported, you may receive current product information, availability and a quotation.
Any transaction is subject to prescription requirements, supplier checks, local law, import rules and final confirmation.
Submitting an enquiry does not guarantee availability, regulatory eligibility, import permission, delivery or a transaction.
Submit a non-binding enquiry. Medicine for World will review the destination country and available options before requesting any sensitive medical documents.
This service cannot assist with medical emergencies or treatment decisions. Contact your treating healthcare professional or local emergency service.
Orforglipron is a prescription-only, once-daily GLP-1 receptor agonist tablet. In the US it is approved as Foundayo for chronic weight management in adults with obesity, or with overweight and at least one weight-related condition, alongside diet and exercise.
No. All three act on the GLP-1 pathway, but orforglipron is a small, non-peptide molecule taken as a daily tablet. Semaglutide is a peptide available as an injection or a tablet with strict fasting rules, and tirzepatide is a weekly injection that also acts on the GIP receptor.
Yes. According to the US label it can be taken at any time of day, with or without food, and without water restrictions. Tablets should be swallowed whole.
Nausea, diarrhoea, constipation, vomiting, abdominal pain and indigestion are the most common. They are most frequent while the dose is being increased. The label also contains a boxed warning about thyroid C-cell tumours.
In the United Kingdom, yes – the MHRA authorisation of 10 August 2026 covers weight management and type 2 diabetes. The current US label covers weight management only. Approved uses differ by country.
3 products represented by their manufacturers or suppliers as containing orforglipron – Luciorfor, Orfomax and Orfoxen – plus the originator Foundayo. It is not a complete global list, and inclusion does not mean that a product is authorised in any specific country.
This page does not establish that. Equivalence, quality and regulatory status depend on each product and each country and must be confirmed with the national medicines authority and your doctor.
Use the non-binding enquiry form on this page. Medicine for World reviews destination-country rules and may ask for a prescription before offering any option. Clicking a brand opens its product page on the Medicine for World website.
Current editorial and medical-review status is shown below. No independent medical review is claimed until it has been completed.
Medical and regulatory facts come from official product information. Product listing details come from a supplied dataset. Numbers in square brackets on this page refer to the sources below.